Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807184 | 0.94 | DRD4 (0.44) | DRD4SMN1; SMN2CYP1A2CYP2C19HTT | |
| SCHEMBL1813495 | 0.90 | CCR3 (0.43) | DRD4SMN1; SMN2CYP1A2CYP2C19HTT | |
| SCHEMBL1808430 | 0.88 | ALDH1A1 (0.44) | DRD4HTTALDH1A1APOBEC3AAPOBEC3G | |
| SCHEMBL1813907 | 0.88 | DRD4 (0.44) | DRD4CYP1A2CYP2C19ALDH1A1SIGMAR1 | |
| SCHEMBL1809472 | 0.82 | ALDH1A1 (0.58) | ALDH1A1RAB9AAPOBEC3AAPOBEC3GNPSR1 | |
| SCHEMBL1809477 | 0.82 | ALDH1A1 (0.58) | ALDH1A1RAB9AAPOBEC3AAPOBEC3GNPSR1 | |
| SCHEMBL1809983 | 0.82 | DRD4 (0.45) | DRD4CYP1A2CYP2C19SIGMAR1 | |
| SCHEMBL1809273 | 0.82 | CCR3 (0.44) | DRD4SMN1; SMN2CYP1A2CYP2C19HTT | |
| SCHEMBL1807203 | 0.81 | DRD4 (0.45) | DRD4SIGMAR1RAB9AKDM4E | |
| SCHEMBL1811262 | 0.81 | CCR3 (0.41) | DRD4SMN1; SMN2HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | DRD4 768/4885SMN1; SMN2 932/4885CYP1A2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.